Talk:COVID-19 drug repurposing research: Difference between revisions

Content deleted Content added

Inline

Latest revision as of 16:32, 17 July 2024

This is the talk page for discussing improvements to the COVID-19 drug repurposing research article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1, 2: 14 days

The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic.

Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page.

COVID-19 High‑importance

	COVID-19 portal This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19
High	This article has been rated as High-importance on the project's importance scale.

Medicine: Society / Pulmonology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Society and Medicine task force (assessed as Mid-importance).
	This article is supported by the Pulmonology task force (assessed as Mid-importance).

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Viruses Mid‑importance

	Viruses portal This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.VirusesWikipedia:WikiProject VirusesTemplate:WikiProject Virusesvirus
Mid	This article has been rated as Mid-importance on the project's importance scale.

Disaster management Mid‑importance

	This article is within the scope of WikiProject Disaster management, a collaborative effort to improve the coverage of Disaster management on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Disaster managementWikipedia:WikiProject Disaster managementTemplate:WikiProject Disaster managementDisaster management
Mid	This article has been rated as Mid-importance on the project's importance scale.

International relations Mid‑importance

	This article is within the scope of WikiProject International relations, a collaborative effort to improve the coverage of International relations on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.International relationsWikipedia:WikiProject International relationsTemplate:WikiProject International relationsInternational relations
Mid	This article has been rated as Mid-importance on the project's importance scale.

WikiProject COVID-19 consensus

WikiProject COVID-19 aims to add to and build consensus for pages relating to COVID-19. They have so far discussed items listed below. Please discuss proposed improvements to them at the project talk page.

General

Superseded by TfD October 2020 and later practice - consult regular {{Current}} guidance.

Refrain from using Worldometer (worldometers.info) as a source due to common errors being observed as noted on the Case Count Task Force common errors page. (April 2020, April 2020)

For infoboxes on the main articles of countries, use Wuhan, Hubei, China for the origin parameter. (March 2020)

"Social distancing" is generally preferred over "physical distancing". (April 2020, May 2020)

Page title

COVID-19 (full caps) is preferable in the body of all articles, and in the title of all articles/category pages/etc.(RM April 2020, including the main article itself, RM March 2021).

SARS-CoV-2 (exact capitalisation and punctuation) is the common name of the virus and should be used for the main article's title, as well as in the body of all articles, and in the title of all other articles/category pages/etc. (June 2022, overturning April 2020)

Map

There is no consensus about which color schemes to use, but they should be consistent within articles as much as possible. There is agreement that there should be six levels of shading, plus gray for areas with no instances or no data. (May 2020)

There is no consensus about whether the legend, the date, and other elements should appear in the map image itself. (May 2020)

For map legends, ranges should use fixed round numbers (as opposed to updating dynamically). There is no consensus on what base population to use for per capita maps. (May 2020)

To ensure you are viewing the current list, you may wish to purge this page.

Treatments for COVID-19: Current consensus

A note on WP:MEDRS: Per this Wikipedia policy, we must rely on the highest quality secondary sources and the recommendations of professional organizations and government bodies when determining the scientific consensus about medical treatments.

Ivermectin: The highest quality sources (1 2 3 4) suggest Ivermectin is not an effective treatment for COVID-19. In all likelihood, ivermectin does not reduce all-cause mortality (moderate certainty) or improve quality of life (high certainty) when used to treat COVID-19 in the outpatient setting (4). Recommendations from relevant organizations can be summarized as: Evidence of efficacy for ivermectin is inconclusive. It should not be used outside of clinical trials. (May 2021, June 2021, June 2021, July 2021, July 2021) (WHO, FDA, IDSA, ASHP, CDC, NIH)
Chloroquine & hydroxychloroquine: The highest quality sources (1 2 3 4) demonstrate that neither is effective for treating COVID-19. These analyses accounted for use both alone and in combination with azithromycin. Some data suggest their usage may worsen outcomes. Recommendations from relevant organizations can be summarized: Neither hydroxychloroquine nor chloroquine should be used, either alone or in combination with azithromycin, in inpatient or outpatient settings. (July 2020, Aug 2020, Sep 2020, May 2021) (WHO, FDA, IDSA, ASHP, NIH)
Ivmmeta.com, c19ivermectin.com, c19hcq.com, hcqmeta.com, trialsitenews.com, etc: These sites are not reliable. The authors are pseudonymous. The findings have not been subject to peer review. We must rely on expert opinion, which describes these sites as unreliable. From published criticisms (1 2 3 4 5), it is clear that these analyses violate basic methodological norms which are known to cause spurious or false conclusions. These analyses include studies which have very small sample sizes, widely different dosages of treatment, open-label designs, different incompatible outcome measures, poor-quality control groups, and ad-hoc un-published trials which themselves did not undergo peer-review. (Dec 2020, Jan 2021, Feb 2021)

Which pages use this template?

Last updated (diff) on 27 February 2023 by Sumanuil (t · c)

Ivermectin and COVID-19

Ivermectin and COVID-19 "Ivermectin Does Not Reduce Risk of Covid Hospitalization, Large Study Finds".

"Effect of Early Treatment with Ivermectin among Patients with Covid-19". doi:10.1056/NEJMoa2115869. {{cite journal}}: Cite journal requires |journal= (help)

2600:1000:B03F:2983:4FD:F300:B6A2:155 (talk) 22:03, 30 March 2022 (UTC)[reply]

Relevance of Zinc

https://www.frontiersin.org/articles/10.3389/fmed.2021.756707/full

https://www.sciencedirect.com/science/article/pii/S2001037021000660

https://www.dovepress.com/the-implications-of-zinc-therapy-in-combating-the-covid-19-global-pand-peer-reviewed-fulltext-article-JIR

https://www.medicalnewstoday.com/articles/can-zinc-levels-predict-covid-19-severity

Drsruli (talk) 19:58, 3 May 2022 (UTC)[reply]

Would need a reliable WP:MEDRS source. Alexbrn (talk) 05:02, 4 May 2022 (UTC)[reply]

Vitamin C

Complete replacement of the contents and references because of newer references available. Same content change at Vitamin C, a Good Article. David notMD (talk) 17:00, 18 December 2023 (UTC)[reply]

@@ Line 1: / Line 1: @@
-{{talk page header |archive_age=14|bot=Lowercase sigmabot III}}
+{{talk page header }}
-{{Ds/talk notice|covid}}
+{{Contentious topics/talk notice|covid}}
-{{WikiProject Banner Shell|collapsed=yes|1=
+{{WikiProject banner shell|collapsed=yes|class=B|1=
-{{WikiProject COVID-19|class=B|importance=high}}
+{{WikiProject COVID-19|importance=high}}
-{{WikiProject Medicine|class=B|importance=mid|society=yes|society-imp=mid|pulmonology=yes|pulmonology-imp=mid}}
+{{WikiProject Medicine|importance=mid|society=yes|society-imp=mid|pulmonology=yes|pulmonology-imp=mid}}
-{{WikiProject Pharmacology|class=B|importance=mid}}
+{{WikiProject Pharmacology|importance=mid}}
-{{WikiProject Viruses |class=B|importance=mid}}
+{{WikiProject Viruses |importance=mid}}
-{{WikiProject Disaster management |class=B|importance=mid}}
+{{WikiProject Disaster management |importance=mid}}
-{{WikiProject International relations |class=B |importance=Mid |needs-infobox=no}}
+{{WikiProject International relations |importance=Mid |needs-infobox=no}}
 }}
 {{Current COVID-19 Project Consensus|collapsed=yes}}
@@ Line 14: / Line 14: @@
 | algo=old(14d)
 | archive=Talk:COVID-19 drug repurposing research/Archive %(counter)d
-| counter=1
+| counter=2
 | maxarchivesize=150K
 | archiveheader={{Automatic archive navigator}}
@@ Line 26: / Line 26: @@
 {{COVID-19 treatments (current consensus)}}
+== Ivermectin and COVID-19 ==
-== Extended-confirmed-protected edit request on 16 September 2021 ==
+Ivermectin and COVID-19
-{{edit extended-protected|COVID-19 drug repurposing research|answered=yes}}
+{{cite newspaper | title=Ivermectin Does Not Reduce Risk of Covid Hospitalization, Large Study Finds | url=https://www.nytimes.com/2022/03/30/health/covid-ivermectin-hospitalization.html }}
-Suggest that the following conclusion from "Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVOC-19" appearing in the American Journal of Therapeutics (2021)be added:
+{{cite journal | title=Effect of Early Treatment with Ivermectin among Patients with Covid-19 |doi=10.1056/NEJMoa2115869}}
-The findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit. . . .  Overall, the evidence also suggests that early use of ivermectin may reduce morbidity and mortality from COVID-19. This is based on (1) reductions in COVID-19 infections when ivermectin was used as prophylaxis, (2) the more favorable effect estimates for mild to moderate disease compared with severe disease for death due to any cause, and (3) on the evidence demonstrating reductions in deterioration. [[Special:Contributions/2601:189:C480:FFB0:0:0:0:CFEE|2601:189:C480:FFB0:0:0:0:CFEE]] ([[User talk:2601:189:C480:FFB0:0:0:0:CFEE|talk]]) 19:06, 16 September 2021 (UTC)
-:[[File:Red information icon with gradient background.svg|20px|link=|alt=]] '''Not done for now:''' please establish a [[Wikipedia:Consensus|consensus]] for this alteration '''[[Wikipedia:Edit requests|before]]''' using the {{tlx|edit extended-protected}} template.<!-- Template:EEp --> This will be "a whole thing." I suggest you seek consensus here on the talk page for that addition. [[User:ScottishFinnishRadish|ScottishFinnishRadish]] ([[User talk:ScottishFinnishRadish|talk]]) 19:16, 16 September 2021 (UTC)
+[[Special:Contributions/2600:1000:B03F:2983:4FD:F300:B6A2:155|2600:1000:B03F:2983:4FD:F300:B6A2:155]] ([[User talk:2600:1000:B03F:2983:4FD:F300:B6A2:155|talk]]) 22:03, 30 March 2022 (UTC)
-== Extended-confirmed-protected edit request on 18 September 2021 ==
+== Relevance of Zinc ==
-{{edit extended-protected|COVID-19 drug repurposing research|answered=yes}}
-I think this article deserves to be included. It is a well sourced and reputable newspaper in India. It writes how the State with the highest population in India used Ivermectin to treat Covid-19 and how it was sanctioned by the State's Health Department.
+https://www.frontiersin.org/articles/10.3389/fmed.2021.756707/full
-[https://indianexpress.com/article/cities/lucknow/uttar-pradesh-government-says-ivermectin-helped-to-keep-deaths-low-7311786/ Uttar Pradesh government says early use of Ivermectin helped to keep positivity, deaths low] [[User:The 13th 4postle|The 13th 4postle]] ([[User talk:The 13th 4postle|talk]]) 15:14, 18 September 2021 (UTC)
-:{{not done}}. Re: India, we already discuss this with other sources that are more recent. Sub-topic discussion of just Uttar Pradesh would be [[WP:UNDUE]]. —&nbsp;[[User:Shibbolethink|<span style="color: black">Shibboleth</span><span style="color: maroon">ink</span>]] <sup>([[User talk:Shibbolethink|♔]]</sup> <sup>[[Special:Contributions/Shibbolethink|♕]])</sup> 15:39, 18 September 2021 (UTC)
+https://www.sciencedirect.com/science/article/pii/S2001037021000660
-== Extended-confirmed-protected edit request on 5 October 2021 ==
+https://www.dovepress.com/the-implications-of-zinc-therapy-in-combating-the-covid-19-global-pand-peer-reviewed-fulltext-article-JIR
-{{Edit extended-protected|COVID-19 drug repurposing research|answered=yes}}
-Change “After reviewing the evidence on ivermectin, the European Medicines Agency (EMA) advised against it's use” to “After reviewing the evidence on ivermectin, the European Medicines Agency (EMA) advised against its use”
+https://www.medicalnewstoday.com/articles/can-zinc-levels-predict-covid-19-severity
-Remove incorrect apostrophe [[User:DarthTaper|DarthTaper]] ([[User talk:DarthTaper|talk]]) 00:23, 5 October 2021 (UTC)
-:{{done}}<!-- Template:EEp --> [[User:Firefangledfeathers|Firefangledfeathers]] ([[User talk:Firefangledfeathers|talk]]) 00:27, 5 October 2021 (UTC)
+[[User:Drsruli|Drsruli]] ([[User talk:Drsruli|talk]]) 19:58, 3 May 2022 (UTC)
-== FDA tweet ==
+:Would need a reliable [[WP:MEDRS]] source. [[User:Alexbrn|Alexbrn]] ([[User talk:Alexbrn|talk]]) 05:02, 4 May 2022 (UTC)
+== Vitamin C ==
-Twitter is not a reliable source, and the informal wording suggests it is not supposed to be taken as an official statement by the FDA. Quoting the tweet without the context of the article that was attached to it is potentially misleading about the scientific reasons for opposing the treatment. Should we remove the tweet? [[User:TWM03|TWM03]] ([[User talk:TWM03|talk]]) 17:58, 20 October 2021 (UTC)
-:I think it should stay. It's a tweet from an official US federal government agency. The article doesn't provide much more context; it's pretty much just "Stop it." [[User:Firefangledfeathers|Firefangledfeathers]] ([[User talk:Firefangledfeathers|talk]]) 18:07, 20 October 2021 (UTC)
+Complete replacement of the contents and references because of newer references available. Same content change at [[Vitamin C]], a Good Article. [[User:David notMD|David notMD]] ([[User talk:David notMD|talk]]) 17:00, 18 December 2023 (UTC)
-::Shouldn't we at least link to the article as per [[WP:HEADLINE]]? [[User:TWM03|TWM03]] ([[User talk:TWM03|talk]]) 18:30, 20 October 2021 (UTC)